Fred Hassan news from FiercePharma
News
U.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related Read more...
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
Fissures in Merck, Schering relationship?
Are fault lines in the Merck/Schering-Plough joint venture beginning to open up? Market-watchers are reading the earnings-call transcripts--and the tea leaves--and finding evidence of "the Read more...
Hassan gets $30M pay package
Fred Hassan (photo) may have his hands full these days, defending Vytorin and Zetia while cutting jobs and costs. But Read more...
ALSO NOTED: J&J reports big revenue growth; Drugmakers fight U.K.'s Aricept ruling;
> Johnson & Johnson reported a 7.7 percent increase in first-quarter sales, to a record-setting $16.2 billion; EPS grew by 8.6 percent to $1.26 excluding special charges. Read more...
A turbulent week for Fred Hassan
Wonder what it was like to be Fred Hassan (photo) last week, when his top products were getting hammered first Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight